Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma

Anti-Cancer Drugs

Volumn 16, Issue 5, 2005, Pages 581-585

  Schrader, Andres J ^a   Heidenreich, Axel ^b   Hegele, Axel ^a   Olbert, Peter ^a   Ohlmann, Garsten H ^b   Varga, Zoltan ^a   Von Knobloch, Rolf ^a   Hofmann, Rainer ^a  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Advanced progressive renal cell carcinoma; Interelukin 2; Interferon; Second line therapy; Thalidomide

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; LAXATIVE; NAVELBINE; RETINOIC ACID; THALIDOMIDE; TOREMIFENE; VINBLASTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; COST BENEFIT ANALYSIS; DISORIENTATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; KIDNEY CARCINOMA; LETHARGY; MALE; NAUSEA; PARALYTIC ILEUS; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 18844391579     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200506000-00014     Document Type: Article

References (33)

1. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163:408-417.
2. Whelan P. The medical treatment of metastatic renal cell carcinoma. EAU Update Ser 2003; 1:237-246.
3. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27:177-186.
4. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
5. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368-1375.
6. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76:824-832.
7. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22:1188-1194.
8. Heidenreich A, Schrader AJ, Varga Z. Basic science and research in renal cell carcinoma: from workbench to bedside. Curr Opin Urol 2003; 13: 457-462.
9. Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 1994; 74:916-919.
10. Wenzel C, Locker GJ, Schmidinger M, Mader R, Kramer G, Marberger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 2002; 39:48-54.
11. Schrader AJ, von Knobloch R, Heidenreich A, Buer J, Hofmann R. Application of retinoids in the treatment of renal cell carcinoma-a futile effort? Anticancer Drugs 2004; 15:819-824.
12. Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmen J, Anttila M, et al. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 2000; 46:27-34.
13. Schmidinger M, Steger GG, Budinsky AC, Wenzel C, Brodowicz T, Locker GJ, et al. Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma. Anticancer Drugs 2000; 11: 175-179.
14. Ravaud A, Trufflandier N, Ferriere JM, Debled M, Palussiere J, Cany L, et al. Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer 2003; 89: 2213-2218.
15. Lopez Hanninen E, Fenner M, Kirchner H, Deckert M, Duensing S, Menzel T, et al. Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma. Cancer Biother 1993; 8:301-306.
16. Paolorossi F, Villa S, Barni S, Tancini G, Andres M, Lissoni P. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. Tumori 1995; 81:45-47.
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
18. Adlard JW. Thalidomide in the treatment of cancer. Anticancer Drugs 2000; 11:787-791.
19. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 2003; 46:S59-S65.
20. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
21. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-715.
22. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593-2602.
23. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21:3351-3356.
24. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003; 21:3770-3776.
25. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13:1029-1035.
26. Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 2002; 20:1429-1430.
27. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002; 95:1629-1636.
28. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, et al. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 2004; 63:1061-1065.
29. Amato RJ, Schell J, Thompson N, Moore R, Miles B. Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 2003; 22:387 (abstr 1556).
30. Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004; 110:260-265.
31. Amato RJ. Thalidomide: an antineoplastic agent. Curr Oncol Rep 2002; 4:56-62.
32. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82:812-817.
33. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002; 95:758-765.